Arcus Biosciences
RCUS
15.62
-0.16
-1.01%
Arcus Biosciences
US · RCUS
#2467 by market cap
Listed 2018
15.62
-0.16
-1.01%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:39
Quant vs Street three independent views, side by side
StockVane factor grade
D
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
2
■ Upgrades■ Downgrades
- 0 upgrades vs 2 downgrades among tracked analyst rating changes.
- Most recent: Morgan Stanley moved from Buy to Hold on 2026-10-20.
Analyst consensus 12 analysts
Buy
Avg price target 41.64 +166.6%
Price target rangecurrent 15.62
Low23.00
Avg41.64
High50.00
Buy 83%
Hold 17%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-09 | J.P. Morgan | -- | Buy | 40.00 |
| 2026-11-06 | Morgan Stanley | -- | Hold | 23.00 |
| 2026-11-05 | Wedbush | -- | Buy | 45.00 |
| 2026-11-04 | Citi | -- | Buy | 50.00 |
| 2026-10-25 | Citi | -- | Buy | 50.00 |
| 2026-10-21 | Truist Financial | -- | Buy | 41.00 |
| 2026-10-21 | Citi | -- | Buy | 50.00 |
| 2026-10-20 | Mizuho Securities | -- | Buy | 47.00 |
| 2026-10-20 | BofA Securities | -- | Hold | 29.00 |
| 2026-10-20 | Morgan Stanley | -- | Hold | 23.00 |
| 2026-10-19 | Goldman Sachs | -- | Buy | 42.00 |
| 2026-10-15 | William Blair | -- | Buy | 50.00 |
| 2026-10-14 | J.P. Morgan | -- | Buy | 41.00 |
| 2026-10-13 | Goldman Sachs | -- | Buy | 42.00 |
| 2026-10-05 | BofA Securities | -- | Hold | 29.00 |
| 2026-10-03 | LifeSci Capital | -- | Buy | 46.00 |
| 2026-09-30 | Wedbush | -- | Buy | 43.00 |
| 2026-09-27 | LifeSci Capital | -- | Buy | 46.00 |
| 2026-09-25 | H.C. Wainwright | -- | Buy | 45.00 |
| 2026-09-24 | LifeSci Capital | -- | Buy | 46.00 |
| 2026-09-16 | TD Cowen | -- | Buy | -- |
| 2026-09-13 | LifeSci Capital | -- | Buy | 46.00 |
| 2026-09-09 | Citi | -- | Buy | 45.00 |
| 2026-09-08 | Truist Financial | -- | Buy | 40.00 |
| 2026-08-11 | BofA Securities | -- | Hold | 29.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-10-20 | Morgan Stanley | Buy → Hold | 23.00 |
| 2026-02-12 | Wells Fargo | Buy → Hold | 23.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-04 | After close | ±12.70% | -8.39% (in line) |
| 2026/Q2 | 2026-08-05 | After close | ±13.29% | +2.27% (in line) |
| 2026/Q1 | 2026-05-05 | After close | ±17.69% | -0.23% (in line) |
| 2025/Q4 | 2026-02-25 | After close | ±24.27% | -3.60% (in line) |
| 2025/Q2 | 2025-08-06 | After close | ±28.40% | -2.21% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±15.39% | -1.35% (in line) |
| 2024/Q4 | 2025-02-25 | After close | ±14.65% | -0.98% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±23.17% | +4.64% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±17.90% | +14.02% (in line) |
| 2024/Q1 | 2024-05-08 | After close | ±12.29% | +5.83% (in line) |
| 2023/Q4 | 2024-02-21 | After close | ±17.65% | +19.87% (beat) |
| 2023/Q3 | 2023-11-07 | After close | ±17.43% | -2.67% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:39:06 · For reference only, not investment advice and not tailored to your situation.
Arcus Biosciences discussion 0 comments